Big pharma investing in regenerative medicine

Large cap pharma and biotech firms have regenerative therapy R&D programs underway according to a recent survey.

69% of respondents are focused on developing cellular-based therapies.

Wound healing and burns have the greatest near-term potential.

Long term areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease.


From other sites
Comments (2)
  • rongood
    , contributor
    Comments (11) | Send Message
    And the news is?
    26 Mar 2014, 09:09 AM Reply Like
  • Joe McCann
    , contributor
    Comments (268) | Send Message
    Should probably mention the MDWD IPO in this since they are a burn play.


    I bought the IPO, but slightly worried if this is true now that MDWD was willing to price at the low end of their range in a M&A hungry landscape.


    Remember Shire bought Advanced BioHealing the night before they IPO'ed, in 2011, so companies are debating M&A vs. IPO right up until the last minute.


    Maybe their product isn't regenerative enough, and really more just burn wound medicine?
    26 Mar 2014, 12:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs